AM-3189 is an orally active and selective GPR40 agonist with EC 50 values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Free Fatty Acid Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.